Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Lurasidone in Patients with Schizophrenia
jRCT2080221817Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221817.